Acquired ring chromosomes in hematological malignancies: A systematic evidence review for diagnostic advances, cytogenomic insights, and clinical significance by an International Consortium on Human Ring Chromosomes (ICHRC) working group.

Cancer GenetJun 1, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)

Maged Zeineldin, Jaclyn B Murry, Dhanlaxmi Shetty et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review by the International Consortium on Human Ring Chromosomes (ICHRC) examines acquired ring chromosomes (aRCs) in hematological malignancies. It highlights the need for advanced genomic analysis to understand the clinical implications of aRCs. The review advocates for integrated cytogenomic analysis to enhance diagnostic interpretation and guide targeted treatments.

Key findings

  • The review emphasizes the importance of genomic copy number aberrations (CNAs) and gene rearrangements in aRCs.
  • Current molecular cytogenetic technologies for aRC analysis are summarized.
  • Evidence supports the need for integrated cytogenomic analysis of aRCs in hematological malignancies.

Why it matters

Understanding the role of acquired ring chromosomes in hematological malignancies can improve diagnostic accuracy and inform treatment strategies. Enhanced genomic insights may lead to better-targeted therapies and improved patient outcomes.

Source

PubMed · PMID 42263477

Published in Cancer Genet. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.